Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
September 09, 2024 16:05 ET
|
Pulmonx Corporation
CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV- 5-year durability data from LIBERATE study demonstrate positive, durable...
Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference
August 29, 2024 16:05 ET
|
Pulmonx Corporation
REDWOOD CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the...
Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference
August 22, 2024 16:05 ET
|
Pulmonx Corporation
REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the...
Pulmonx Reports Second Quarter 2024 Financial Results
July 31, 2024 16:05 ET
|
Pulmonx Corporation
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today...
Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference
July 29, 2024 16:05 ET
|
Pulmonx Corporation
REDWOOD CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the...
Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024
July 10, 2024 16:05 ET
|
Pulmonx Corporation
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it...
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 06, 2024 17:03 ET
|
Pulmonx Corporation
REDWOOD CITY, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today...
Pulmonx Reports First Quarter 2024 Financial Results
May 01, 2024 16:05 ET
|
Pulmonx Corporation
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today...
Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024
April 10, 2024 16:05 ET
|
Pulmonx Corporation
REDWOOD CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it...
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
April 02, 2024 16:05 ET
|
Pulmonx Corporation
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today...